Login to Your Account



Other News To Note


Monday, December 5, 2011
• Northwest Biotherapeutics Inc., of Bethesda, Md., said it implemented a restructuring to reduce its liabilities from $48 million to $16.5 million, removing $31.5 million through settlement, retirement and conversion. The firm said the move will strengthen its balance sheet as it accelerates its 240-patient Phase II trial of its lead dendritic cell-based vaccine in glioblastoma multiforme. Northwest also recently received clearance for a Phase III trial in prostate cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription